KA/EN
Register
Medicines reference
Search
Search
Product

Brovanol M

Favourites

Niclosamide + Oxibendazole + Levamisole · Brovapharma LLC

1 form: tablet. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
92/12/16 mg tablets, Tablet · Cat Cat 1 tablet per 4 kg
Kittens: total course 1 tablet/4 kg (one quarter tablet/kg), divided into two equal portions 24 hours apart. This equals 23 mg/kg niclosamide + 3 mg/kg oxibendazole + 4 mg/kg levamisole hydrochloride over the course, half per administration. First labelled deworming is at 6 weeks. Below 4 kg the calculated per-administration fraction may be a quarter or one eighth of a tablet although the physical tablet has one score; do not estimate tiny fragments by eye. Do not use with intestinal atony or exceed the dose.
 · split total dose into 2 equal portions 24 hours apart; continue prevention by risk		 split total dose into 2 equal portions 24 hours apart; continue prevention by risk Georgia Yes, veterinary
In force until 12 Apr 2027
Veterinary (National Food Agency)
In the register: ბროვანოლი M
№ 000012
Verified on: 23 Oct 2026
92/12/16 mg tablets, Tablet · Dog Dog 1 tablet per 4 kg
Puppies: total course 1 tablet/4 kg (one quarter tablet/kg), divided into two equal portions 24 hours apart. This equals 23 mg/kg niclosamide + 3 mg/kg oxibendazole + 4 mg/kg levamisole hydrochloride over the course, half per administration. First labelled deworming is at 4-5 weeks before vaccination. Below 4 kg the calculated per-administration fraction may be a quarter or one eighth of a tablet although the physical tablet has one score; do not estimate tiny fragments by eye. Do not use with intestinal atony or exceed the dose.
 · split total dose into 2 equal portions 24 hours apart; continue prevention by risk		 split total dose into 2 equal portions 24 hours apart; continue prevention by risk Georgia Yes, veterinary
In force until 12 Apr 2027
Veterinary (National Food Agency)
In the register: ბროვანოლი M
№ 000012
Verified on: 23 Oct 2026
Details: pack, label wording, sources, registration

Brovanol M 92/12/16 mg tablets, Tablet

N10 for puppies and kittens
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Complete authorised puppy role: treatment and prevention of mixed gastrointestinal larval/adult nematode and preadult/adult cestode infections across the named canine label spectrum
4.2/10
Weak evidence support
vetman assessment

Brovanol M

92/12/16 mg tablets, N10 for puppies and kittens
Assessed clinical scopeDog · Complete authorised puppy role: treatment and prevention of mixed gastrointestinal larval/adult nematode and preadult/adult cestode infections across the named canine label spectrum · By mouth
Care settingVeterinarian-selected juvenile oral deworming after weight, parasite risk and clinical status review, with two accurately measured portions 24 hours apart, response/fecal follow-up and species-appropriate ongoing control
vetman score 4.2/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000012 · Verified on 23 Oct 2026

A legally registered, clearly identified puppy tablet with plausible three-class breadth, but no exact outcome study and substantially lower/split component exposures than applicable evidence or authorised comparators. Sparse juvenile safety and difficult quarter/eighth-tablet administration restrict it to a weak, carefully supervised option rather than a dependable broad-spectrum first choice.

Regulatory and scientific credibility5.5/10

Exact composition, scored-tablet description, complete named spectrum, species/age starts, divided regimen, core contraindication and storage are transparent in a current registered manufacturer leaflet and current Georgian authorisation. However no internationally recognised regulator authorises the exact product, no public assessment/outcome dossier or target-animal safety study was found, and EU/GB/US exact authorisation is absent.

Clinical efficacy3.0/10

The three classes are pharmacologically plausible, but no controlled exact-combination outcome was found. The total course supplies only 3 mg/kg oxibendazole versus 15 mg/kg in applicable dog/cat efficacy evidence and 23 mg/kg niclosamide versus 120 mg/kg in an authorised comparator; levamisole hydrochloride is 4 mg/kg total and all three are split over two days. Additive activity is possible but cannot validate the broad larval/adult and cestode label at these exposures.

Safety and tolerability4.5/10

Low calculated exposures may limit acute toxicity, and the label names intestinal atony, no-overdose and transient post-kill GI/skin signs. Yet levamisole has a 4-6 safety index and potentially severe cholinergic/respiratory toxicity; exact juvenile safety, interactions, pregnancy/lactation, illness/organ-disease and overdose management are missing.

Clinical practicality3.5/10

Two oral administrations are short, but the total quarter-tablet/kg course must be halved again: a 2 kg puppy needs one quarter tablet and a 1 kg puppy one eighth tablet per administration, despite one physical score. This makes accurate dosing difficult in the exact young target group and requires an accurately dispensable alternative when fragments cannot be measured.

Full-course cost-effectiveness-

Current Georgian price for the exact N10 presentation and weight-adjusted complete course was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete label scope: named nematodes include Ancylostoma, Uncinaria, Toxocara, Toxascaris and Trichuris; named cestodes include Dipylidium, Diphyllobothrium and Taenia, with larval/preadult and adult wording. Do not extend “some others” to an unnamed parasite or claim heartworm, lungworm, protozoal or ectoparasite activity.
  • Dose is a total course of one quarter tablet/kg, divided into two equal portions 24 hours apart—not one quarter tablet/kg on each day. This delivers total niclosamide 23 mg/kg, oxibendazole 3 mg/kg and levamisole hydrochloride 4 mg/kg; document weight, total fraction and each portion.
  • The label starts puppies at 4-5 weeks before vaccination. A 2 kg puppy needs one quarter tablet and a 1 kg puppy one eighth tablet per administration, but the tablet has one score; do not estimate an unmeasurable fragment—use an accurately dispensable alternative.
  • No controlled exact-product outcome was found. Exact total oxibendazole exposure is one fifth of the 15 mg/kg dog/cat evidence dose and niclosamide is below the 120 mg/kg authorised comparator; splitting the lower amounts over two days makes the evidence bridge weaker, not stronger.
  • Do not use with intestinal atony or exceed the dose. Levamisole has a narrower 4-6 safety index; salivation, tremor, ataxia, urination/defecation, collapse or breathing difficulty after excess or interaction exposure requires urgent veterinary treatment and respiratory support.
  • Strong worm burden may be followed by transient urticaria, perianal itching, restlessness, diarrhoea or vomiting attributed by the label to parasite breakdown. Severe, persistent or systemic signs should not be dismissed as expected die-off; reassess hydration, obstruction, dose and diagnosis.
  • The exact leaflet does not establish safety in pregnancy/lactation, debilitated or malnourished juveniles, liver/kidney disease or repeated courses. It also supplies no target-animal safety margins or adverse-event frequencies; perform a patient-specific benefit-risk review.
  • No adequate exact interaction study was found. Because levamisole is cholinergic, avoid unreviewed concurrent organophosphates, other cholinesterase inhibitors or cholinergic anthelmintics; review every antiparasitic and recent pesticide exposure before dosing.
  • The manufacturer suggests prevention every 3-4 months, but puppy/kitten control must follow age, maternal transmission, exposure, geography, zoonotic risk and faecal testing. Current guidance commonly starts Toxocara control earlier and repeats more frequently in early life; do not let one course delay appropriate follow-up.
  • Store dry and dark at 1-25 C out of children's reach. Verify the exact N10 92/12/16 mg scored tablet, authorisation 000012, lot and expiry; do not substitute Brovanol Plus, Brovanol D or a livestock formulation, whose actives, dose and safety differ.
Assessment sources
  1. Brovanol M GE register2026
  2. Brovanol M exact leaflet2025
  3. Brovanol M manufacturer2025
  4. Anthelmintic safety2025
  5. Oxibendazole dog/cat study1998
  6. Niclosamide dog study1977
  7. VITAMINTHE comparator SPC2026
  8. Vetminth EU comparator2026
  9. ESCCAP worm control GL12026
  10. WAAVP efficacy standard2023
  11. GB VMD anthelmintic endpoint2026
  12. FDA Drontal positive control1993
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Complete authorised kitten role: treatment and prevention of mixed gastrointestinal larval/adult nematode and preadult/adult cestode infections across the named feline label spectrum
4.0/10
Weak evidence support
vetman assessment

Brovanol M

92/12/16 mg tablets, N10 for puppies and kittens
Assessed clinical scopeCat · Complete authorised kitten role: treatment and prevention of mixed gastrointestinal larval/adult nematode and preadult/adult cestode infections across the named feline label spectrum · By mouth
Care settingVeterinarian-selected juvenile oral deworming after weight, parasite risk and clinical status review, with two accurately measured portions 24 hours apart, response/fecal follow-up and species-appropriate ongoing control
vetman score 4.0/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000012 · Verified on 23 Oct 2026

A legally registered kitten-labelled tablet, but exact efficacy and feline safety are not demonstrated, component exposures are materially below applicable comparators and the divided dose commonly requires an unscored one-eighth tablet. It is a weak supervised option when accurate dosing and follow-up are assured, not a robust routine kitten first choice.

Regulatory and scientific credibility5.5/10

Exact composition, scored-tablet description, complete named spectrum, species/age starts, divided regimen, core contraindication and storage are transparent in a current registered manufacturer leaflet and current Georgian authorisation. However no internationally recognised regulator authorises the exact product, no public assessment/outcome dossier or target-animal safety study was found, and EU/GB/US exact authorisation is absent.

Clinical efficacy3.0/10

The three classes are pharmacologically plausible, but no controlled exact-combination outcome was found. The total course supplies only 3 mg/kg oxibendazole versus 15 mg/kg in applicable dog/cat efficacy evidence and 23 mg/kg niclosamide versus 120 mg/kg in an authorised comparator; levamisole hydrochloride is 4 mg/kg total and all three are split over two days. Additive activity is possible but cannot validate the broad larval/adult and cestode label at these exposures.

Safety and tolerability4.0/10

The low calculated exposures and named transient post-kill signs are reassuring only indirectly. Exact kitten levamisole/three-drug safety data, adverse-event denominators, interactions, pregnancy/lactation, illness/organ-disease and overdose management are missing, while levamisole has a 4-6 safety index and potentially severe cholinergic/respiratory toxicity.

Clinical practicality3.0/10

Two administrations are short, but many six-week kittens are near or below 1 kg and therefore require about one eighth tablet per administration, despite one physical score. Accurate dosing and complete ingestion are poor fits for the exact target population; an accurately dispensable kitten formulation is often more workable.

Full-course cost-effectiveness-

Current Georgian price for the exact N10 presentation and weight-adjusted complete course was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Complete label scope: named nematodes include Ancylostoma, Uncinaria, Toxocara, Toxascaris and Trichuris; named cestodes include Dipylidium, Diphyllobothrium and Taenia, with larval/preadult and adult wording. Do not extend “some others” to an unnamed parasite or claim heartworm, lungworm, protozoal or ectoparasite activity.
  • Dose is a total course of one quarter tablet/kg, divided into two equal portions 24 hours apart—not one quarter tablet/kg on each day. This delivers total niclosamide 23 mg/kg, oxibendazole 3 mg/kg and levamisole hydrochloride 4 mg/kg; document weight, total fraction and each portion.
  • The label starts kittens at 6 weeks. A 1 kg kitten needs one eighth tablet per administration, but the tablet has one score; do not estimate an unmeasurable fragment—use an accurately dispensable kitten alternative.
  • No controlled exact-product outcome was found. Exact total oxibendazole exposure is one fifth of the 15 mg/kg dog/cat evidence dose and niclosamide is below the 120 mg/kg authorised comparator; splitting the lower amounts over two days makes the evidence bridge weaker, not stronger.
  • Do not use with intestinal atony or exceed the dose. Levamisole has a narrower 4-6 safety index; salivation, tremor, ataxia, urination/defecation, collapse or breathing difficulty after excess or interaction exposure requires urgent veterinary treatment and respiratory support.
  • Strong worm burden may be followed by transient urticaria, perianal itching, restlessness, diarrhoea or vomiting attributed by the label to parasite breakdown. Severe, persistent or systemic signs should not be dismissed as expected die-off; reassess hydration, obstruction, dose and diagnosis.
  • The exact leaflet does not establish safety in pregnancy/lactation, debilitated or malnourished juveniles, liver/kidney disease or repeated courses. It also supplies no target-animal safety margins or adverse-event frequencies; perform a patient-specific benefit-risk review.
  • No adequate exact interaction study was found. Because levamisole is cholinergic, avoid unreviewed concurrent organophosphates, other cholinesterase inhibitors or cholinergic anthelmintics; review every antiparasitic and recent pesticide exposure before dosing.
  • The manufacturer suggests prevention every 3-4 months, but puppy/kitten control must follow age, maternal transmission, exposure, geography, zoonotic risk and faecal testing. Current guidance commonly starts Toxocara control earlier and repeats more frequently in early life; do not let one course delay appropriate follow-up.
  • Store dry and dark at 1-25 C out of children's reach. Verify the exact N10 92/12/16 mg scored tablet, authorisation 000012, lot and expiry; do not substitute Brovanol Plus, Brovanol D or a livestock formulation, whose actives, dose and safety differ.
Assessment sources
  1. Brovanol M GE register2026
  2. Brovanol M exact leaflet2025
  3. Brovanol M manufacturer2025
  4. Anthelmintic safety2025
  5. Oxibendazole dog/cat study1998
  6. Niclosamide dog study1977
  7. VITAMINTHE comparator SPC2026
  8. Vetminth EU comparator2026
  9. ESCCAP worm control GL12026
  10. WAAVP efficacy standard2023
  11. GB VMD anthelmintic endpoint2026
  12. FDA Drontal positive control1993
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Niclosamide92 mg/tablet Oxibendazole12 mg/tablet Levamisole16 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Brovapharma LLC · Ukraine
Manufacturer (register)
Brovapharma Ltd, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 604, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 12 Apr 2027
Veterinary (National Food Agency)
In the register: ბროვანოლი M
№ 000012
Verified on: 23 Oct 2026
 EU No
Verified on: 23 Oct 2026
 UK No
Verified on: 23 Oct 2026
 US No
Verified on: 23 Oct 2026
Controlled in Georgia
Unknown
Information not fully verified Total course: 1 tablet per 4 kg (one quarter tablet/kg), divided into two equal portions 24 hours apart. Puppies: first labelled use at 4-5 weeks before vaccination; kittens: 6 weeks. A 1 kg animal therefore needs one eighth tablet per administration, but the tablet has only one score; use an accurately dispensable alternative when the calculated fraction cannot be measured reliably. Subsequent control should follow parasite/species/exposure risk and faecal findings rather than an automatic calendar alone.
DoseSpeciesWeightRouteFrequencySource
1 tablet per 4 kg
Kittens: total course 1 tablet/4 kg (one quarter tablet/kg), divided into two equal portions 24 hours apart. This equals 23 mg/kg niclosamide + 3 mg/kg oxibendazole + 4 mg/kg levamisole hydrochloride over the course, half per administration. First labelled deworming is at 6 weeks. Below 4 kg the calculated per-administration fraction may be a quarter or one eighth of a tablet although the physical tablet has one score; do not estimate tiny fragments by eye. Do not use with intestinal atony or exceed the dose.
 Cat Any weight By mouth split total dose into 2 equal portions 24 hours apart; continue prevention by risk
Brovapharma Brovanol M
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Brovanol M tablets - official registered manufacturer leaflet
Brovapharma official registered leaflet, 2026
1 tablet per 4 kg
Puppies: total course 1 tablet/4 kg (one quarter tablet/kg), divided into two equal portions 24 hours apart. This equals 23 mg/kg niclosamide + 3 mg/kg oxibendazole + 4 mg/kg levamisole hydrochloride over the course, half per administration. First labelled deworming is at 4-5 weeks before vaccination. Below 4 kg the calculated per-administration fraction may be a quarter or one eighth of a tablet although the physical tablet has one score; do not estimate tiny fragments by eye. Do not use with intestinal atony or exceed the dose.
 Dog Any weight By mouth split total dose into 2 equal portions 24 hours apart; continue prevention by risk
Brovapharma Brovanol M
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Brovanol M tablets - official registered manufacturer leaflet
Brovapharma official registered leaflet, 2026

Niclosamide: No dose supported by a publicly verifiable source yet

Oxibendazole: No dose supported by a publicly verifiable source yet

Levamisole: No dose supported by a publicly verifiable source yet

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗